17 February 2026

Agronomics Limited

("Agronomics" or the "Company")

Unaudited Interim Results for the six-month period ending 31 December 2025

Agronomics Limited (AIM:ANIC), a leading listed company in the field of clean food, is pleased to announce its unaudited interim results for the six-month period ending 31 December 2025. A copy of these Interim Results is available on the Company's website www.agronomics.im.

James Mellon, Chair of Agronomics, commented:

"The Company recorded a net profit for the period of £10,012,753 (31 December 2024: loss of £6,555,201). During the six months period, net investment gains (loan and cash interest income, net unrealised investment gains/losses, net unrealised foreign exchange gains/losses) totalled £10,714,736 (31 December 2024: net investment losses of £5,872,621). No performance fees were payable or accrued for the current period. The basic and diluted profit per share was 0.991 pence (31 December 2024: loss per share of 0.649 pence)."

Financial highlights

·      The Company's Net Asset Value per Share at 31 December 2025 was 13.78 pence (30 June 2025: 12.34 pence) - an increase of 11.7%. The share price of 6.2 pence at the 31 December 2025 close represented a discount of 55% to the 31 December 2025 NAV per share.

·      Net investment gains (loan and cash interest income, net unrealised investment gains/losses, net unrealised foreign exchange gains/losses) totalled £10,714,736 (31 December 2024: net investment losses of £5,872,621) during the six-month period.

·      Operating expenses for the period were £701,983 (31 December 2024: £682,580).

·      A net profit of £10,012,753 (31 December 2024: loss of £6,555,201) was recognised during the period.

·      The carrying amount of invested assets at the half year was £137,954,854  (30 June 2025: £121,009,941), and cash and cash equivalents and cash deposits stood at £2,153,140 (30 June 2025: £3,606,187).

·      Net assets increased to £139,973,458 at 31 December 2025 (30 June 2025: £124,520,935). The increase in NAV is due to:

o  Unrealised fair value gain on the Blue Nalu carrying amount following the close of its preferred share and convertible promissory note raise - £4 million;

o  Unrealised fair value loss on the Solar Foods Oyj carrying amount, with the carrying amount adjusted to fair value based on latest traded share price - £0.9 million;

o  Unrealised fair value gain on the Liberation Bioindustries carrying amount following the close of its Series A 1 equity raise - £4.1 million;

o  Unrealised foreign exchange gains on investments held in USD, EUR and AUD - £2.8 million;

o  Net operating costs for the period of £0.7 million;

o  Net loss offset by net interest income earned on loan investments and cash deposits - £0.7 million.

o  Increase in NAV of £1 million, following the issue 6,488,535 new Agronomics shares to Supermeat The Essence of Meat Ltd ("Supermeat"), in settlement of a US$ 1.25 million SAFE investment; and

o  Increase in NAV of £4.5 million, following the issue of 30,643,003 new Agronomics shares to Blue Nalu Inc, in settlement of a US$ 6,000,000 Preferred Shares investment.

Operational Highlights

·      On 24 July 2025, Solar Foods Oyj announced that, in partnership with Japanese food manufacturer Ajinomoto Co. Inc, it introduced a Solein®-powered Flowering Ice Cream in connection with the World Aquatics Championships, Singapore 2025;

·      On 12 September 2025, Clean Food Group Limited reported it received approval for its CLEAN Oil™ 25 product to be used as a cosmetic ingredient in the United Kingdom, Europe, and the United States;

·      On 23 September 2025, Onego Bio Limited announced that the U.S. Food and Drug Administration ("FDA") issued a "no questions" letter regarding the company's conclusion that its flagship product, marketed as Bioalbumen®, is Generally Recognized As Safe ("GRAS") under its conditions of use in a wide range of food and beverage applications;

·      25 September 2025 - Clean Food Group complete the acquisition of a fermentation plant from Algal Omega 3 Ltd, providing immediate access to one million litres of fermentation capacity and materially accelerating its path to commercial scale;

·      21 October 2025 - Geltor Inc received a 'No Questions' Letter from the US Food and Drug Administration, confirming the Generally Recognized As Safe status of its PrimaColl® ingredient - the world's first biodesigned vegan collagen polypeptide;

·      10 November 2025 - the EVERY Company completed a US$ 55 million Series D financing round, led by McWin Capital Partners through the McWin Food Tech Fund, and included participation from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian Company Limited (an affiliate of Agronomics), and SOSV;

·      21 November 2025 - SuperMeat completed a US$ 3.5 million funding round through the issue of a Simple Agreement for Future Equity of which Agronomics invested US$ 2 million in the form of US$ 0.75 million in cash and US$ 1.25 million in new Agronomics shares, with Milk and Honey Ventures also investing;

·      19 December 2025 - Liberation Bioindustries, Inc closed the first tranche of its Series A1 equity round, which included the conversion of all Convertible Loan Note instruments held by Agronomics into Series A1 shares; and

·      30 December 2025 - Blue Nalu Inc completed an initial closing of a Convertible Promissory Note ("CPN") financing, with invested proceeds of approximately US$ 8 million, and Agronomics subscribing for US$ 600,000 of CPNs. The CPN funding was led by experienced investors in food tech, including Lewis & Clark AgriFood Fund II LLP and Siddhi Capital Fund I L.P. Concurrently, Agronomics subscribed for new Preferred Shares worth US$ 6 million.

Post-Period End Highlights

·      15 January 2026 - Completed an additional investment of AU$3 million in its portfolio company, All G Co Holdings Pty Limited ("All G"), an Australian biotech specialising in precision fermentation of human and bovine milk proteins, notably lactoferrin. The consideration due from Agronomics under the Note Purchase Agreement has been satisfied in full by the issue of 10,026,375 new Ordinary Shares of the Company, each new share issued at a price equal to 14.65 pence (being the net asset value per share as at 30 September 2025).

The Company also announced, on 19 December 2025, that the board and shareholders of its portfolio company, Meatable B.V, resolved to dissolve the legal entity and its related group companies and to terminate all operating activities. This resulted in a full write down of the investments carrying amount, totalling £11.9 million, with the impairment being recognised in the audited June 2025 financial statements.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU No. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

For further information please contact:

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Unaudited Interim Report and Condensed Financial Statements

For the period ended 31 December 2025

Chair's statement

I am pleased to present the Unaudited Interim Results for Agronomics Limited (the "Company" or "Agronomics") for the six-month period ending 31 December 2025.

Portfolio Progress

During the period, the Agronomics portfolio made meaningful progress across several of its more advanced investments, with a growing number of companies moving beyond technical validation and into commercial execution, regulatory clearance, and scaled manufacturing. While the wider funding environment for clean food companies has remained challenging, our portfolio continues to demonstrate the resilience of its underlying technologies and the relevance of its solutions to global food system constraints.

Precision fermentation remains the area of strongest momentum within the portfolio. Multiple companies achieved regulatory milestones that materially advance their commercial prospects. Onego Bio received a "No Questions" letter from the U.S. Food and Drug Administration for its Bioalbumen® egg protein, concluding it as is Generally Recognized As Safe ("GRAS") and enabling commercial deployment across a broad range of food applications. Clean Food Group secured regulatory approval for its CLEAN Oil™ 25 product for use in cosmetics across the UK, Europe, and the United States, unlocking access to a large, high-value end market and validating the scalability of its proprietary fermentation platform.

Commercial traction has also continued to build. Solar Foods Oyj, in partnership with Ajinomoto, introduced Solein®-powered consumer products in connection with the World Aquatics Championships in Singapore, further demonstrating customer acceptance of novel proteins produced via biomanufacturing. The EVERY Company closed a US$ 55 million Series D financing round and commenced nationwide retail rollout in the United States, reflecting both increasing demand for stable egg protein supply and growing confidence from strategic and institutional investors.

A key development during the period was the continued progress of portfolio companies focused on manufacturing infrastructure. Clean Food Group acquired the assets of Algal Omega 3, providing immediate access to one million litres of fermentation capacity and materially accelerating its path to commercial scale. Liberation Bioindustries closed the first tranche of its Series A1 equity round, with its Richmond facility nearing completion and partners already preparing to utilise capacity upon commissioning. We believe this growing availability of industrial-scale biomanufacturing capacity represents a critical inflection point for the sector.

Within cultivated proteins, progress has been more uneven, reflecting both the capital intensity and longer development timelines of this segment. Agronomics increased its investment in SuperMeat The Essence of Meat Ltd to support continued commercialisation of cultivated chicken in Europe and participated in BlueNalu Inc's convertible promissory note and equity round, increasing our ownership while strengthening downside protection. At the same time, following an extended period of funding constraints, Meatable B.V entered an orderly wind-down, resulting in a full write-off of our position. While disappointing, this outcome underscores the importance of disciplined portfolio management and reinforces our focus on supporting companies with clear pathways to scale and capital efficiency.

Overall, despite a demanding operating environment, the period was characterised by tangible progress across regulation, commercial partnerships, and manufacturing readiness. These developments continue to support our conviction that a smaller number of well-capitalised, execution-focused companies will emerge stronger as the sector matures.

At 31 December 2025, the weighting of the investment portfolio was as follows:

Investment Strategy

Agronomics' strategy has not changed. We continue to invest in companies developing technologies that can materially improve the way food and food ingredients are produced, with a clear focus on scalability, capital discipline and defensible intellectual property.

Over the past 6-month period, our emphasis has increasingly been on precision fermentation. This part of the portfolio is now showing tangible commercial progress, supported by regulatory approvals, customer partnerships and growing manufacturing capacity. In our view, precision fermentation offers the most credible near-term route to large-scale adoption, particularly in functional proteins and specialty ingredients where performance, reliability of supply and cost matter more than novelty.

A key element of our approach is supporting the infrastructure required to enable this transition. Limited access to industrial biomanufacturing capacity has been one of the main constraints facing the sector. Investments in platforms such as Liberation Bioindustries and Clean Food Group are intended to address this bottleneck directly, allowing multiple downstream companies to scale more quickly and efficiently. We see this as an important enabler not just for individual portfolio companies, but for the sector as a whole.

Our approach to cultivated proteins remains selective. While the long-term case for cultivated meat and seafood remains intact, these businesses typically require more capital and longer development timelines. We therefore focus on companies that demonstrate technical progress, realistic cost-reduction pathways and a credible route to regulatory approval and commercialisation. We also expect further consolidation in this area and continue to manage our exposure accordingly.

We maintain a disciplined valuation policy, carrying unquoted investments at the price of the most recent funding round in accordance with IFRS. This approach avoids anticipating value creation ahead of market evidence and provides consistency during periods of volatility.

Looking ahead, we remain convinced that food security, supply chain resilience and sustainability will continue to drive demand for the technologies in which we invest. While funding conditions are likely to remain challenging in the near term, we believe this environment favours companies that are well capitalised, operationally focused and able to execute. Agronomics will continue to support such businesses and deploy capital selectively where we see the strongest long-term opportunities.

A Year of Expected Growth

The year ahead is expected to mark an important transition for several of our portfolio companies, as a growing number move from development into commercial execution. In precision fermentation in particular, regulatory approvals, customer partnerships and manufacturing capacity are now in place, allowing companies to begin supplying products at scale rather than in limited pilots.

This shift from technical validation to commercial delivery is significant. It reflects years of investment in platform development and is now being reinforced by customer demand for more stable, secure and cost-predictable ingredient supply chains. As a result, the focus for the coming year will increasingly be on execution, reliability and the ability to convert early traction into recurring revenues.

We also expect continued consolidation across the sector. While this has reduced the number of active companies, it has strengthened those that remain, with capital and management attention now more tightly aligned to commercial outcomes. For Agronomics, this environment favours portfolio companies that are operationally focused and able to scale within existing infrastructure.

Although challenges remain, particularly in accessing capital, we believe the portfolio is better positioned today than at any point previously to benefit from this shift. The coming year is therefore less about experimentation and more about proving that these technologies can operate as part of the global food system.

Financial Review

The Company recorded a net profit for the period of £10,012,754 (31 December 2024: loss of £6,555,201). During the six months period, net investment gains (loan and cash interest income, net unrealised investment gains/losses, net unrealised foreign exchange gains/losses) totalled £10,714,736 (31 December 2024: net investment losses of £5,872,621). No performance fees were payable or accrued for the current period. The basic and diluted profit per share was 0.991 pence (31 December 2024: loss per share of 0.649 pence).

The net profit recognised during the period includes:

·      Unrealised fair value gain on the Blue Nalu carrying amount following the close of its preferred share and convertible promissory note raise - £4 million;

·      Unrealised fair value loss on the Solar Foods Oyj carrying amount, with the carrying amount adjusted to fair value based on latest traded share price - £0.9 million;

·      Unrealised fair value gain on the Liberation Bioindustries carrying amount following the close of its Series A 1 equity raise - £4.1 million;

·      Unrealised foreign exchange gains on investments held in USD, EUR and AUD - £2.8 million;

·      Net operating costs for the period of £0.7 million;

·      Net loss offset by net interest income earned on loan investments and cash deposits - £0.7 million.

The carrying amount of invested assets is £137,954,854 (30 June 2025: £121,009,941), and cash and cash equivalents and bank deposits stood £2,153,140 (30 June 2025: £3,606,187). Our net assets increased to £139,973,459 at 31 December 2025 (30 June 2025: £124,520,935). At the period end the company had 1,015,905,830 ordinary shares in issue.  As a result, the net asset value per share at 31 December 2025 is 13.78 pence, which is an increase of 11.7% from 30 June 2025 (12.34 pence).

Investment Strategy and Outlook

Looking ahead, Agronomics will continue to focus on supporting portfolio companies that are making tangible progress toward commercial scale, while maintaining a disciplined and selective approach to capital allocation. Our strategy remains centred on technologies that address structural challenges in food production, particularly those that can deliver secure supply, consistent quality and predictable economics. As parts of the sector move into commercial execution, our emphasis is increasingly on operational performance, customer adoption and the ability of businesses to scale within realistic capital constraints.

While the investment environment is likely to remain uneven, we believe this period favours companies with proven platforms, experienced management teams and a clear route to revenue generation. Consolidation across the sector is expected to continue, and we will actively manage the portfolio to ensure exposure remains aligned with long-term value creation. With a more focused portfolio and increasing participation in businesses entering commercial phases, Agronomics is well positioned to support the next stage of growth while remaining prudent in the deployment of capital.

Jim Mellon

Chair

16 February 2026

Condensed statement of comprehensive income

For the period ended 31 December 2025

The Directors consider that the Company's activities are continuing.

Condensed statement of financial position

As at 31 December 2025

These interim financial statements were approved by the Board of Directors on 16 February 2026 and were signed on their behalf by:

Denham Eke

Director